DAB389IL-2 (ONTAK): A Novel Fusion Toxin Therapy for Lymphoma

Clinical Lymphoma

Volumn 1, Issue 2, 2000, Pages 110-116

  Foss, Francine M ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Cutaneous T cell lymphoma; Fusion toxins; Interleukin 2 receptor; Lymphoma

Indexed keywords

DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

ADULT; CLINICAL TRIAL; HUMAN; LYMPHOMA; METABOLISM; MIDDLE AGED; REVIEW;

ADULT; CLINICAL TRIALS; DIPHTHERIA TOXIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTOXINS; INTERLEUKIN-2; LYMPHOMA; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS;

EID: 0034280315     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.n.009     Document Type: Review

References (29)

1. Waldmann TA. The multichain interleukin 2 receptor. A target for immunotherapy in lymphoma, autoimmune disorders, and organ allografts. JAMA 1990; 263:272-274.
2. Craig F, Banks P. Detection of the alpha and beta components of the interleukin-2 receptor using immunologic techniques. Mol Pathol 1992; 5:118a (Abstract).
3. Moya M, Dautry-Varsat A, Goud B, et al. Inhibition of coated pit formation in Hep2 cells blocks the cytotoxicity of diphtheria toxin but not that of ricin toxin. J Cell Biol 1985; 101:548-559.
4. Morris RE, Gerstein AS, Bonventre PF, et al. Receptor-mediated entry of diphtheria toxin into monkey kidney (Vero) cells: electron microscopic evaluation. Infect Immun 1985; 50:721-727.
5. Fuchs R, Schmid S, Mellman I. A possible role for Na+,K+-ATPase in regulating ATP-dependent endosome acidification. Proc Natl Acad Sci U S A 1989; 86:539-543.
6. Kagan BL, Finkelstein A, colombini M. Diphtheria toxin fragment forms large pores in phospholipid bilayer membranes. Proc Natl Acad Sci USA 1981; 78:4950-4954.
7. Donovan JJ, Simon MI, Draper RK, et al. Diphtheria toxin forms trans-membrane channels in planar lipid bilayers. Proc Natl Acad Sci USA 1981; 78:172-176.
8. Williams DP, Parker K. Bacha P, et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng 1987; 1:493-498.
9. Bacha P, Williams DP, Waters C, et al. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med 1988; 167:612-622.
10. Walz G, Zanker B, Brand K, et al. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation. Proc Natl Acad Sci USA 1989; 86:9485-9488.
11. Waldmann TA. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986; 232:727-732.
12. Strauchen JA, Breakstone BA. IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am J Pathol 1987; 126:506-512.
13. Sheibani K, Winberg CD, van de Velde S, et al. Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases. An J Pathol 1987; 127:27-37.
14. Barnett D, Wilson GA, Lawrence AC, et al. The interleukin-2 receptor and its expression in the acute leukaemias and lymphoproliferative disorders. Dis Markers 1988; 6:133-139.
15. Rosolen A, Nakanishi M, Poplack DG, et al. Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies. Blood 1989; 73:1968-1972.
16. Kung E, Meissner K, Loning T. Cutaneous T cell lymphoma: immunocytochemical study on activation/proliferation and differentiation associated antigens in lymph nodes, skin, and peripheral blood. Virchows Arch A Pathol Anat Histopathol 1988; 413:539-549.
17. LeMaistre CF, Meneghetti C, Rosenblum M, et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992; 79:2547-2554.
18. Tepler I, Schwartz G, Parker K, et al. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 1994; 73:1276-1285.
19. Hesketh P, Caguioa P, Koh H, et al. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol 1993; 11:1682-1690.
20. LeMaistre CF. Craig FE, Meneghetti C, et al. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res 1993; 53:3930-3934.
21. Kuzel TM, Rosen ST, Gordon LI, et al. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. Leuk Lymphoma 1993; 11:369-377.
22. Foss FM, Borkowski TA, Gilliom M, et al. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 1994; 84:1765-1774.
23. Kiyokawa T, Williams DP, Snider CE, et al. Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells. Protein Eng 1991; 4:463-468.
24. LeMaistre CF, Saleh MN, Kuzel TM, et al. Phase I trial of a ligand fusionprotein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998; 91:399-405.
25. Saleh MN, LeMaistre CF, Kuzel TM, et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J An Acad Dermatol 1998; 39:63-73.
26. Duvic M, Kuzel T, Olsen E, et al. Quality of life is significantly improved in CTCL patients who responded to DAB389IL-2 (ONTAK) fusion protein. Blood 1998; 92:624a (Abstract #2572).
27. Olsen EA, Duvic M, Frankel A, et al. Pivotal phase III trial of two doses of DAB-IL2 (ONTAK) for the treatment of cutaneous T-cell lymphoma. J Clin Oncol:In Press.
28. Foss F, Bacha P, Kuzel T. Biological correlates of acute hypersensitivity events with DAB389IL-2 in non-Hodgkin's lymphoma: decreased frequency and severity with steroid premedication. Blood 1999; 94:98a (Abstract #431).
29. Foss FM, Bacha P, Nichols J, et al. Immunohistochemical detection of the p55 component of the high-affinity interleukin-2 receptor alone in sufficient to predict for response to DAB389IL2 (ONTAK). Proc Am Soc Clin Oncol 1999; 18:14a (Abstract #48).